Can hemodialysis technique modify the hypercatabolic state?

Renal Failure

Volumn 18, Issue 3, 1996, Pages 395-404

  Sunder Plassmann, Gere ^a   Hörl, Walter H ^a,b  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CONFERENCE PAPER; DETOXIFICATION; EXTRACORPOREAL CIRCULATION; HEMODIALYSIS; INFECTION; LYMPHOCYTE ACTIVATION; NITROGEN BALANCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; SEPSIS; SURVIVAL RATE; TECHNIQUE; ULTRAFILTRATION;

EID: 0029978493     PISSN: 0886022X     EISSN: None     Source Type: Journal    
DOI: 10.3109/08860229609052809     Document Type: Conference Paper

References (70)

1. Borah MF, Schoenfeld PY, Gotch FA, Sargent JA, Wolfson M, Humphreys MH: Nitrogen balance during intermittent dialysis therapy of uremia. Kidney Int 14:491-500, 1978.
2. Wolfson M, Jones MR, Kopple J: Amino acid losses during hemodialysis with infusion of amino acids and glucose. Kidney Int 21:500-506, 1982.
3. Ward RA, Shirlow MJ, Hayes JM, Chapman GV, Farrell PC: Protein catabolism during hemodialysis. Am J Clin Nutr 32:2443-2449, 1979.
4. Gutierrez A, Alvestrand A, Wahren J, Bergström J: Effect of in vivo contact between blood and dialysis membranes on protein catabolism in humans. Kidney Int 38:487-494, 1990.
5. Gutierrez A, Bergström J, Alvestrand A: Protein catabolism in sham-hemodialysis: the effect of different membranes. Clin Nephrol 38:20-29, 1992.
6. Urena P, Herbelin A, Zingraff J, Lair M, Man NK, Descamps-Latscha B, Drueke T: Permeability of cellulosic and non-cellulosic membranes to endotoxin subunits and cytokine production during in vitro haemodialysis. Nephrol Dial Transplant 7:16-28, 1992.
7. Canivet E, Lavaud S, Wong T, Guenounou M, Willemin JC, Potron G, Chanard J: Cuprophane but not synthetic membrane induces increases in serum tumor necrosis factor-alpha levels during hemodialysis. Am J Kidney Dis 23:41-46, 1994.
8. Henderson LW, Koch KM, Dinarello CA, Shaldon S: Hemodialysis hypotension: the interleukin hypothesis. Blood Purif 1:3-8, 1983.
9. Löfberg E, Wernerman J, Noree LO, Von der Decken A, Vinnars E: Ribosome and free amino acid content in muscle during hemodialysis. Kidney Int 39:984-989, 1991.
10. Lim VS, Bier DM, Flanigan M, Sum Ping ST: The effect of hemodialysis on protein metabolism. J Am Soc Nephrol 1:366, 1990.
11. Dinarello CA: Agents provocateurs in hemodialysis? Kidney Int 41:683-694, 1992.
12. Haeffner-Cavaillon N, Cavaillon JM, Laude M, Kazachtkine MD: C3a (C3a des Arg) induces production and release of interleukine 1 by cultured human monocytes. J Immunol 139:794-799, 1987.
13. Schindler R, Gelfand JA, Dinarello CA: Recombinant C5a stimulates transcription rather than translation of IL-1 and TNF: translational signal provided by LPS or IL-1 itself. Blood 76:1631-1638, 1990.
14. Cavaillon JM, Fitting C, Haeffner-Cavaillon N: Recombinant C5a enhances interleukin-1 and tumor necrosis factor release by lipopolysaccharide-stimulated monocytes and macrophages. Eur J Immunol 20:253-257, 1990.
15. Betz M, Haensch GM, Rauterberg EW, Bommer J, Ritz E. Cuprammonium membranes stimulate interleukin-1 release and arachidonic acid metabolism in monocytes in the absence of complement. Kidney Int 34:67-73, 1988.
16. Evans RC, Holmes CJ: In vitro study of the transfer of cytokine-inducing substances across selected high-flux hemodialysis membranes. Blood Purif 9:92-101, 1991.
17. Aderka D, Engelmann H, Maor Y, Brakesbusch C, Wallach D: Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 175:323-329, 1992.
18. Dinarello CA: Interleukin-1 and tumor necrosis factor and their naturally occurring antagonists during hemodialysis. Kidney Int 42(suppl 38):S68-S77, 1992.
19. Sunder-Plassmann G, Kapiotis S, Gasche C, Klaar U: Functional characterization of cytokine autoantibodies in chronic renal failure patients. Kidney Int 45:1484-1488, 1994.
20. Herbelin A, Nguyen AT, Urena P, Descamps-Latscha B: Induction of cytokines by dialysis membranes in normal whole blood: a new in vitro assay for evaluating membrane biocompatibility. Blood Purif 10:40-52, 1992.
21. Mault JR, Kresowick TF, Dechert RE, Arnoldi DK, Swartz RD, Bartlett RH: CAVH: The answer to starvation in acute renal failure. Trans Am Soc Artif Org 30:203-206, 1984.
22. Chima CS, Meyer L, Hummell AC, Bosworth C, Heyka R, Paganini EP, Werynski A: Protein catabolic rate in patients with acute renal failure on continuous arteriovenous hemofiltration and total parenteral nutrition. J Am Soc Nephrol 3:1516-1521, 1993.
23. Clark WR, Mueller BA, Alaka KJ, Macias WL: A comparison of metabolic control by continuous and intermittent therapies in acute renal failure. J Am Soc Nephrol 4:1413-1420, 1994.
24. van Bommel EFH, Bouvy ND, So KL, Zietse R, Vincent HH, Bruining HA, Weimar W: Acute dialytic support for the critically ill. intermittent hemodialysis versus continuous arteriovenous hemodiafiltration. Am J Nephrol 15.192-200, 1995.
25. Bellomo R, Farmer M, Wright C, Parkin G, Boyce N: Treatment of sepsis-associated severe acute renal failure with continuous hemodiafiltration: clinical experience and comparison with conventional dialysis. Blood Purif 13:246-254, 1995.
26. Manns M, Siegler MH, Teehan BP, Dixit K: Renal function changes during intermittent hemodialysis (IHD) in critically ill patients with acute renal failure (ARF). Blood Purif 12:188, 1994 (abstract).
27. Ronco C: Continuous renal replacement therapies for the treatment of acute renal failure in intensive care patients. Clin Nephrol 3:187-198, 1993.
28. Storck M, Hartl WH, Zimmerer E, Inthorn D: Comparison of pump-driven and spontaneous continuous haemofilration in postoperative acute renal failure. Lancet 337.452-455, 1991.
29. Gotloib L, Barzilay E, Shustak A, Lev A: Sequential hemofiltration in nonoliguric high capillary permeability pulmonary edema of severe sepsis: preliminary report. Crit Care Med 12:997-1000, 1984.
30. Coraim F, Wolner E: Management of cardiac surgery patients with continuous arteriovenous hemofiltration In HG Siebarth, H Mann, eds., Continuous Arteriovenous Hemofiltration (CAVH), International Conference on CAVH, Aachen, FRG, November 2-3, Basel, Switzerland, Karger, 1985, pp 103-110.
31. Coraim F, Fasol R, Stellwag F, Wolner E: Continuous arteriovenous hemofiltration (CAVH) after cardiac surgery. In HG Sieberth, H Mann, eds., Continuous Arteriovenous Hemofiltration (CAVH), International Conference on CAVH, Aachen, FRG, November 2-3, 1984, Basel, Switzerland, Karger, 1985, pp 116-124.
32. Ossenkoppele GJ, van der Meulen J, Bronsveld W, Thijs LG: Continuous arteriovenous hemofiltration as an adjunctive therapy for septic shock. Crit Care Med 13:102-104, 1985.
33. Radzivil GG, Beloborodov VB, Broniakin Iu V, Roslyi IM, Gracheva AM: Hemosorption as a method of treating endotoxicosis in patients with septic shock of meningococcal etiology. Anesteziol Reanimatol 2: 46-50, 1987.
34. Gotloib L, Barzilay E, Shustak A, Wais Z, Jaichenko J, Lev A: Hemofiltration in septic ARDS. the artificial kidney as an artificial endocrine lung. Resuscitation 13:123-132, 1986.
35. Zobel G, Trop M, Ring E, Grubbauer HM: Arteriovenous hemofiltration in children with multiple organ system failure Int J Artif Org 10:233-238, 1987.
36. Barzilay E, Kessler D, Berlot G, Gullo A, Geber D, Zeev IB: Use of extracorporeal supportive techniques as additional treatment for septic-induced multiple organ failure patients. Crit Care Med 17:634-637, 1989.
37. Lee PA, Matson JR, Pryor RW, Hinshaw LB: Continuous arteriovenous hemofiltration therapy for Staphylococcus aureus-induced septicemia in immature swine. Crit Care Med 21:914-924, 1993.
38. Bellomo R, Tipping P, Boyce N: Tumor necrosis factor clearances during veno-venous hemodiafiltration in the critically ill. ASAIO Trans 37:M322-M323, 1991.
39. Bellomo R, Tipping P, Boyce N: Continuous veno-venous hemofiltration with dialysis removes cytokines from the circulation of septic patients. Crit Care Med 21:522-526, 1993.
40. Elliott D, Wiles CE, Reynolds HN: Removal of cytokines in septic patients using continuous veno-venous hemodiafiltration. Crit Care Med 22:718-719, 1994 (letter).
41. Millar AB, Armstrong L, van der Linden J, Moat N, Ekroth R, Westwick J, Scallan M, Lincoln C: Cytokine production and hemofiltration in children undergoing cardiopulmonary bypass. Ann Thorac Surg 56:1499-1502, 1993.
42. Byrick RJ, Goldstein MB, Wong PY: Increased plasma tumor necrosis factor concentration in severe rhabdomyolysis is not reduced by continuous arteriovenous hemodialysis. Crit Care Med 20:1483-1486, 1992.
43. Kierdorf HR: Einfluß der kontinuierlichen Hämofiltration auf Proteinkatabolismus, Mediatorsubstanzen und Prognose des akuten Nierenversagens im Multiorganversagen. Habilitationsschrift, Universität Aachen, 1993.
44. Andreasson S, Göthberg S, Berggren H, Bengtsson A, Eriksson E, Risberg B: Hemofiltration modifies complement activation after extracorporeal circulation in infants. Ann Thorac Surg 56:1515-1517, 1993.
45. Mahiout A, Courtney JM: Effect of dialyser membranes on extracellular and intracellular granulocyte and monocyte activation in ex vivo pyrogen-free conditions. Biomaterials 15:969-980, 1994.
46. Schetz M: Removal of cytokines in septic patients using continuous veno-venous hemodiafiltration. Crit Care Med 4:715-716, 1994 (letter).
47. Beutler B: Endotoxin, tumor necrosis factor, and related mediators: new approaches to shock. New Horizons 1:3-12, 1993.
48. Böhrer H, Schmidt H, Bach A, Motsch J, Martin E: Removal of cytokines in septic patients using continuous veno-venous hemodiafiltration. Crit Care Med 4:717-718, 1994 (letter).
49. Grootendorst AF, van Bommel EFH: The role of hemofiltration in the critically-ill intensive care unit patient: present and future Blood Purif 11:209-223, 1993.
50. Schiffl H, Lang SM, König A, Strasser T, Haider MC, Held E: Biocompatible membranes in acute renal failure: prospective case-controlled study. Lancet 344:570-572, 1994.
51. Hakim RM, Wingard RL, Parker RA: Effect of the dialysis membrane in the treatment of patients with acute renal failure. N Engl J Med 331:1338-1342, 1994.
52. Himmelfarb J, Lazarus M, Hakim R: Reactive oxygen species production by monocytes and polymorphonuclear leukocytes during dialysis. Am J Kidney Dis 17:271-278, 1991.
53. Himmelfarb J, Ault KA, Holbrook D, Leeber DA, Hakim RM: Intradialytic granulocyte reactive oxygen species production: a prospective crossover trial. J Am Soc Nephrol 4:178-186, 1993.
54. Vanholder R, Ringoir S, Dhondt A, Hakim RM: Phagocytosis in uremic and hemodialysis patients: a prospective and cross sectional study. Kidney Int 39:320-327, 1991.
55. Cristol JP, Canaud B, Rabesandratana H, Gaillard I, Serre A, Mion C: Enhancement of reative oxygen sepsices production and cell surface markers expression due to haemodialysis. Nephrol Dial Transplant 9:389-394, 1994.
56. Himmelfarb J, Hakim RM: Biocompatibility and risk of infection in haemodialysis patients. Nephrol Dial Transplant 9(suppl 2):138-144, 1994.
57. Woodrow G, Turney JH: Cause of death in acute renal failure. Nephrol Dial Transplant 7:230-234, 1992.
58. Schulman G, Fogo A, Gung A, Badr K, Hakim R: Complement activation retards resolution of ischemic renal failure in the rat. Kidney Int 40:1069-1074, 1991.
59. Hornberger JC, Chernew M, Petersen J, Garber AM: A multivariate analysis of mortality and hospital admissions with high-flux dialysis. J Am Soc Nephrol 3:1227-1237, 1992.
60. Tanaka H, Sugimoto H, Yoshioka T, Sugimoto T: Role of granulocyte elastase in tissue injury in patients with septic shock complicated by multiple-organ failure. Ann Surg 213:81-85, 1991.
61. Tanaka H, Ogura H, Yokota J, Sugimotot H, Yoshioka T, Sugimotot T: Acceleration of superoxide production from leukocytes in trauma patients. Ann Surg 214:187-192, 1991.
62. 1-antitrypsin and lactoferrin in sepsis: evidence for neutrophils as mediators in fatal sepsis. J Lab Clin Med 119:159-168, 1992.
63. Gardinali M, Padalino P, Vesconi S, Calcagno A, Ciappellano S, Conciato L, Chiara O, Agostoni A, Nespoli A: Complement activation and polymorphonuclear neutrophil leukocyte elastase in sepsis. Arch Surg 127:1219-1224, 1992.
64. Bone RC: Inhibitors of complement and neutrophils: a critical evaluation of their role in the treatment of sepsis. Crit Care Med 20:891-898, 1992.
65. Dofferhoff ASM, De Jong HJ, Bom VJJ, Van der Meer J, Limburg PC, De Vries-Hospers HG, Marrink J, Mulder POM, Weits J: Complement activation and the production of inflammatory mediators during the treatment of severe sepsis in humans. Scand J Infect Dis 24:197-204, 1992.
66. Hörl WH, Schaefer RM, Hörl M, Heidland A: Neutrophil activation in acute renal failure and sepsis. Arch Surg 125:651-654, 1990.
67. Craddock PR, Hammerschmidt DE: Complement-mediated granulocyte activation and down-regulation during hemodialysis. ASAIO J 7:50-56, 1984.
68. Lo SK, Detmers PA, Levin SM, Wright SD: Transient adhesion of neutrophils to endothelium. J Exp Med 169:1779-1793, 1989.
69. Himmelfarb J, Gerard NP, Hakim RM: Intradialytic modulation of granulocyte C5a receptors. J Am Soc Nephrol 2:920-926, 1991.
70. Haag-Weber M, Hörl WH: Can the hypercatabolic state in acute renal failure be modified by treatment? In VE Andreucci, LG Fine, eds., International Yearbook of Nephrology, Nephrol Dial Transplant 9(suppl):105-109, 1994.